Document:

Exhibit 10.1

      

    

    CONSULTING AGREEMENT WITH BLUE OCEAN ACQUISITION CORP

     

    THIS CONSULTING AGREEMENT (this “Agreement”) is made and effected as of November 22, 2022 (the “Effective Date”), by and between Blue Ocean Acquisition Corp, a Cayman Islands exempted company (the “Company”),
        and Matt Lasov, residing for notice purposes at 2 Wisconsin Circle, 7th Floor, 7th Floor Chevy Chase MD 20815 (“Consultant”) (each a “Party” and collectively, the “Parties”).

     

    WHEREAS, the Company is
        a special purpose acquisition company (Nasdaq: BOCN) formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses or entities (the “Business Combination”);

     

    WHEREAS, the Company
        desires to retain Consultant as an independent contractor to serve as the Chief Financial Officer (“CFO”) of the Company; and

     

    WHEREAS, the Consultant
        wishes to accept such engagement on the terms and conditions set forth herein;

     

    NOW, THEREFORE, in
        consideration of the foregoing recitals, the mutual covenants of the parties hereinafter set forth and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

     

    1.  Engagement

     

    1.1          The Company hereby engages Consultant as
          an independent contractor to serve as CFO of the Company.  Consultant will have such responsibilities, duties and authority, and will render such services for and in
            connection with the Company and its affiliates as are customary in such position in a comparable company and as the Chairman or the Board of Directors of the Company (the “Board”) shall from time to time reasonably direct (the “Consulting Services”).  Consultant shall perform all
          Consulting Services diligently and to the best of Consultant’s professional ability and judgment.

     

    1.2          As disclosed in our Prospectus, the
          Company’s executive officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations and our search for a business
          combination and their other businesses. We understand that you, like each of our other executive officers, are engaged in other business endeavors for which you may be entitled to substantial compensation, and you are not obligated to contribute
          any specific number of hours per week to the Company’s affairs.

     

    2.            Term

     

    2.1          Subject to the terms of this Agreement,
          Consultant shall provide the Consulting Services from the Effective Date to and concluding on the earlier of the date on which the Company completes the Business Combination or the redemption of the Company’s public shares should it not complete
          a Business Combination in accordance with the Company’s amended and restated memorandum and articles of association (such period, the “Term”).

     

    
      
        

    

    
    2.2          Notwithstanding any other provision in
          this Agreement to the contrary, the Term shall terminate effective on the date indicated upon the happening of any of the following events:

     

    a. Upon the death of Consultant, effective immediately on the date of death without any notice;

     

    b. Upon at least 30 days’ written notice by either Consultant or the Company to the other Party.

     

    3.           Payment
          to Consultant

     

    The Company agrees to pay Consultant a bonus of One Hundred and Fifty Thousand United States Dollars ($150,000) within 10 business days of the close of the
      Business Combination (the “Success Bonus”).  Consultant understands that if the Company does not complete a Business Combination, or if the Term
      hereunder expires prior to completion of a Business Combination, no Success Bonus shall be due or paid to Consultant.

     

    4.           Relationship
          of Parties

     

    4.1          The Parties acknowledge and agree that
          Consultant is being retained hereunder solely as an independent contractor, will not be considered an employee  of the Company for any purpose, and hereby waives participation in and shall not receive any employee benefits.  Consultant is solely
          responsible for the payment of any and all applicable federal, state, local and other taxes relating to all Consulting Fees paid or payable to Consultant. Nothing in this Agreement shall be construed to constitute an employment relationships,
          partnership, or joint venture between the Parties.  The Company will not make disability insurance contributions on behalf of Consultant, or obtain workers' compensation insurance on behalf of Consultant.

     

    5.           Confidentiality;
          Return of Company Property

     

    5.1          Except as required by law or as otherwise set forth in this Agreement, Consultant will not at any time during or after the Term directly or indirectly disclose any Confidential Information. "Confidential Information" as used herein includes but is not limited to all confidential competitive, pricing, marketing, proprietary, trade secret
          (as defined under applicable law) and other information or materials relating or belonging to the Company (whether or not reduced to writing) or provided by a third party on a confidential basis, including without limitation all non-public
          information furnished or disclosed to or otherwise obtained by Consultant in the course of the Consultant’s provision of the Consulting Services. "Confidential Information" does not include information that lawfully and properly becomes publicly
          known outside of the Company, other than through a breach by Consultant of this Agreement or some other obligation.

     

    5.2          Upon the termination
          of the Term or earlier upon written demand of Company, Consultant shall immediately return to Company, all Company property, including any Confidential Information in the possession of Consultant.

     

    
      2

      
        

    

    5.3          Notwithstanding
          anything in this Agreement to the contrary, nothing in this Agreement prohibits Consultant from confidentially or otherwise communicating or filing a charge or complaint with, participating in an investigation by, or giving truthful testimony or
          statements to, a governmental agency or regulatory entity, in each case without receiving prior authorization from or having to disclose any such conduct to Company, or from responding if properly subpoenaed or otherwise required to do so under
          applicable law.  U.S. federal law provides that an individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made (x) in confidence to a Federal, State, or
          local government official (either directly or indirectly) or to an attorney, solely for the purpose of reporting or investigating a suspected violation of law; or (y) in a complaint or other document filed in a lawsuit or other proceeding, if
          such filing is made under seal.  An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in
          the court proceeding, if the individual—(i) files any document containing the trade secret under seal; and (ii) does not disclose the trade secret, except pursuant to court order.

     

    6.           Assignment

     

    Neither this Agreement nor any rights or obligations under this Agreement shall be transferable or assignable by Consultant without the prior written consent of
      the Company.  Any attempted transfer or assignment that violates this paragraph, or any other term of this Agreement, shall be void.

     

    7.           Governing
          Law and Jurisdiction

     

    This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York, without giving effect to conflicts of law
      principles that would result in the application of the substantive laws of another jurisdiction.  The Parties (i) agree that any action, proceeding, claim or dispute arising out of, or relating in any way to, this Agreement shall be brought and
      enforced in the courts of New York City, in the State of New York, and irrevocably submit to such jurisdiction and venue, which jurisdiction and venue shall be exclusive and (ii) waive any objection to such exclusive jurisdiction and venue or that
      such courts represent an inconvenient forum.

     

    8.           Miscellaneous

     

    Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof.  This Agreement constitutes the
      entire agreement between the Parties and hereby supersedes all prior and contemporaneous drafts, writings or oral statements.  This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto.

     

    9.           Counterparts and Facsimile Signatures.

     

    This Agreement may be executed in counterparts and by facsimile or electronic mail (including .pdf or any electronic signature complying with
      the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) execution, each of which shall be deemed an original, but all of which taken together shall constitute one
      and the same instrument.

     

    
      3

      
        

    

    IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first written above in the Preamble.

     

    	 	
            Blue Ocean Acquisition Corp

          
	 	 
	 	
            By:

          	
            /s/ Richard Leggett

          	 

    

    

    	 	
            Name:

          	
            Richard Leggett

          	 

    

    

    	 	
            Title:

          	
            Chief Executive Officer

          	 

    

    

    	 	
            Matt Lasov

          
	 	 
	 	
            /s/ Matt Lasov

          	 

    

    

    

    

    
      4EX-10.1

 Exhibit 10.1 

FORM OF WARRANT 

ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT 

This Assignment, Assumption and Amendment Agreement (this “Agreement”) is made as of November 22, 2022, by and among
Frazier Lifesciences Acquisition Corporation, a Cayman Islands exempted company (“FLAC”), NewAmsterdam Pharma Company B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid)
incorporated under the laws of the Netherlands (“Holdco”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”). 

WHEREAS, FLAC and the Warrant Agent are parties to that certain Warrant Agreement, dated as of December 8, 2020, and the form of
which was filed with the United States Securities and Exchange Commission on November 20, 2020 (the “Existing Warrant Agreement”); 

WHEREAS, capitalized terms used herein, but not otherwise defined, shall have the meanings given to such terms in the Existing Warrant
Agreement; 
 WHEREAS, pursuant to the Existing Warrant Agreement, FLAC issued (i) 167,000 private placement warrants to the Sponsor
(collectively, the “Private Placement Warrants”) to purchase FLAC’s Class A ordinary shares, par value $0.0001 per share (“Class A Shares”), with each Private Placement Warrant being
exercisable for one Class A Share and with an exercise price of $11.50 per share, and (ii) 4,600,000 warrants as part of the units issued to public investors in the Offering (the “Public Warrants” and together with the Private
Placement Warrants, the “Warrants”) to purchase Class A Shares, with each whole Public Warrant being exercisable for one Class A Share and with an exercise price of $11.50 per share; 

WHEREAS, all of the Warrants are governed by the Existing Warrant Agreement; 

WHEREAS, on July 25, 2022, Holdco, FLAC, NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company
(“Merger Sub”) and NewAmsterdam Pharma Holding B.V., a private company with limited liability (besloten vennootschap met beperkte aansprakelijkheid) incorporated under the laws of the Netherlands, entered into that certain
Business Combination Agreement (“BCA”); 
 WHEREAS, pursuant to the BCA, the parties thereto agreed to enter into a
business combination as part of which, among other things, Merger Sub will merge with and into FLAC, with FLAC surviving such merger as a wholly-owned subsidiary of Holdco (the “Merger”) and in such Merger, each Warrant that is
outstanding immediately prior to the effective date of the Merger (as determined in accordance with the applicable terms and conditions set forth in the BCA, the “Effective Date”) shall automatically cease to represent a right to
acquire Class A Shares and shall, subject to the terms and conditions set forth in the BCA and in this Agreement, automatically represent, immediately following the Effective Date, a right to acquire ordinary shares in the share capital of
Holdco (“Holdco Shares”) on the same contractual terms and conditions as were in effect immediately prior to the Effective Date under the Existing Warrant Agreement (the “Warrant Exchange”); 

 WHEREAS, the Board of Directors of FLAC has determined that the consummation of the
transactions contemplated by the BCA will constitute a Business Combination for the purposes of the Existing Warrant Agreement; 

WHEREAS, the Warrant Exchange in connection with such Business Combination is permitted under Section 4.5 of the Existing Warrant
Agreement and does not require the consent of any Registered Holders; 
 WHEREAS, Section 9.8 of the Existing Warrant Agreement
provides that FLAC and the Warrant Agent may amend the Existing Warrant Agreement without the consent of any Registered Holders for the purpose of curing any ambiguity, or correcting any mistake or defective provision contained therein or adding or
changing any other provisions with respect to matters or questions arising under the Existing Warrant Agreement as FLAC and the Warrant Agent may deem necessary or desirable and that FLAC and the Warrant Agent deem shall not adversely affect the
interest of the Registered Holders; and 
 WHEREAS, in connection with the Merger and the Warrant Exchange, FLAC desires to assign
all of its right, title and interest in the Existing Warrant Agreement to Holdco and Holdco wishes to accept such assignment. 
 NOW,
THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree
as follows. 
 1.    Assignment and Assumption; Consent. 

1.1    Assignment and Assumption. FLAC hereby assigns to Holdco all of FLAC’s right, title and interest in and
to the Existing Warrant Agreement (as amended hereby) as of the Effective Date and Holdco hereby assumes, and agrees to pay, perform, satisfy and discharge in full, as the same become due, all of FLAC’s liabilities and obligations under the
Existing Warrant Agreement (as amended hereby) arising from and after the Effective Date. 
 1.2    Consent.
The Warrant Agent hereby consents to the assignment of the Existing Warrant Agreement by FLAC to Holdco pursuant to Section 1.1 hereof effective as of the Effective Date, and the assumption of the Existing Warrant
Agreement by Holdco from FLAC pursuant to Section 1.1 hereof effective as of the Effective Date, and to the continuation of the Existing Warrant Agreement in full force and effect from and after the Effective Date, subject
at all times to the Existing Warrant Agreement (as amended hereby) and to all of the provisions, covenants, agreements, terms and conditions of the Existing Warrant Agreement and this Agreement. 

2.    Amendment of Existing Warrant Agreement. FLAC and the Warrant Agent hereby amend the Existing Warrant
Agreement as provided in this Section 2, effective as of the Effective Date, and acknowledge and agree that the amendments to the Existing Warrant Agreement set forth in this Section 2 are
necessary or desirable and that such amendments do not adversely affect the interests of the Registered Holders. 

  
 -2- 

 2.1    Preamble. The preamble on page one of the Existing
Warrant Agreement is hereby amended by deleting “Frazier Lifesciences Acquisition Corporation, a Cayman Islands exempted company” and replacing it with “NewAmsterdam Pharma Company N.V., a public limited liability company (naamloze
vennootschap) incorporated under the laws of the Netherlands.” As a result thereof, all references to the “Company” in the Existing Warrant Agreement shall be references to NewAmsterdam Pharma Company N.V. rather than Frazier
Lifesciences Acquisition Corporation. 
 2.2    Reference to Holdco Shares. All references to “Ordinary
Shares” or “Class A ordinary shares” in the Existing Warrant Agreement (including all Exhibits thereto) shall mean “ordinary shares in the share capital of Holdco.” 

2.3    Exercise Period. For purposes of the determination of the Exercise Period pursuant to Section 3.2 of
the Existing Warrant Agreement as a result of the Merger, references to “the date on which the Company completes its initial Business Combination” shall be references to the “Final Closing Date,” as such term is defined in the
BCA. 
 2.4    Notice. The address for notices to the Company set forth in Section 9.2 of the
Existing Warrant Agreement is hereby amended and restated in its entirety as follows: 
 Gooimeer
2-35 
 1411 DC Naarden 

The Netherlands 
 Attention:
Louise Kooij 
 Email: louise.kooij@newamsterdampharma.com 

3.    Miscellaneous Provisions. 

3.1    Effectiveness of Warrant. Each of the parties hereto acknowledges and agrees that the effectiveness of this
Agreement shall be expressly subject to the occurrence of the Merger and shall automatically be terminated and shall be null and void if the BCA shall be terminated for any reason. 

3.2    Successors. All the covenants and provisions of this Agreement by or for the benefit of Holdco or the
Warrant Agent shall bind and inure to the benefit of their respective successors and assigns. 

3.3    Severability. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term
or provision hereof shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall
be added as a part of this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible and be valid and enforceable. 

3.4    Applicable Law. The validity, interpretation and performance of this Agreement shall be governed in
all respects by the laws of the State of New York, without giving effect to conflict of law principles that would result in the application of the substantive laws of another jurisdiction. The parties hereby agree that any action, proceeding or
claim against a party 

  
 -3- 

 
arising out of or relating in any way to this Agreement shall be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New
York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. Each of the parties hereby waives any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. 

3.5    Examination of the Warrant Agreement. A copy of this Agreement shall be available at all reasonable times at
the office of the Warrant Agent in the Borough of Manhattan, City and State of New York, for inspection by the registered holder of any Warrant. The Warrant Agent may require any such holder to submit his Warrant for inspection by it. 

3.6    Counterparts. This Agreement may be executed in any number of original or facsimile counterparts and each of
such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. 

3.7    Effect of Headings. The section headings herein are for convenience only and are not part of this Agreement
and shall not affect the interpretation thereof. 
 3.8    Entire Agreement. This Agreement and the
Existing Warrant Agreement, as modified by this Agreement, constitutes the entire understanding of the parties and supersedes all prior agreements, understandings, arrangements, promises and commitments, whether written or oral, express or implied,
relating to the subject matter hereof, and all such prior agreements, understandings, arrangements, promises and commitments are hereby canceled and terminated. 

[Remainder of page intentionally left blank.] 

  
 -4- 

 IN WITNESS WHEREOF, FLAC, Holdco and the Warrant Agent have duly executed this
Agreement, all as of the date first written above. 
  

			
	FRAZIER LIFESCIENCES ACQUISITION CORPORATION
		
	By:	 	 /s/ James N. Topper

	Name:	 	James N. Topper
	Title:	 	Chief Executive Officer
	
	NEWAMSTERDAM PHARMA COMPANY B.V.
		
	By:	 	 /s/ Michael Davidson

	Name:	 	Michael Davidson
	Title:	 	Chief Executive Officer
	
	CONTINENTAL STOCK TRANSFER & TRUST COMPANY
		
	By:	 	 /s/ Margaret B. Lloyd

	Name:	 	Margaret B. Lloyd
	Title:	 	Vice President

 [Signature Page to Warrant Assignment, Assumption and Amendment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]